Mechanism of action
Aripiprazole functions as a dopamine system stabilizer through partial agonism at dopamine D2 receptors. In areas of high dopaminergic activity (such as the mesolimbic pathway in psychosis), it acts as a functional antagonist by competing with endogenous dopamine. In areas of low dopaminergic tone (such as the mesocortical pathway), it provides modest stimulation. This dual action theoretically addresses both positive and negative symptoms of schizophrenia while minimizing extrapyramidal side effects and hyperprolactinemia.
Aripiprazole also acts as a partial agonist at serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The 5-HT1A partial agonism may contribute to anxiolytic and antidepressant effects, while 5-HT2A antagonism reduces the risk of extrapyramidal symptoms and may improve negative symptoms and cognition.
Unlike typical antipsychotics and many atypical agents, aripiprazole has minimal affinity for histamine H1, muscarinic, and alpha-adrenergic receptors. This pharmacologic profile accounts for its lower propensity for sedation, weight gain, orthostatic hypotension, and anticholinergic effects compared to drugs such as olanzapine, clozapine, or quetiapine.
- Aripiprazole is a dopamine partial agonist (dopamine system stabilizer) at D2 receptors, unique among antipsychotics
- Akathisia is the most common side effect and most frequent reason for discontinuation
- Lower risk of metabolic syndrome, weight gain, and hyperprolactinemia compared to other atypical antipsychotics
- Metabolized by CYP2D6 and CYP3A4; dose adjustment required with strong inhibitors (reduce 50%) or inducers (double dose)
- Long half-life (~75 hours) allows once-daily dosing; steady state reached in 2 weeks
- FDA-approved as adjunctive treatment for major depressive disorder (added to antidepressants)
- Black box warning: increased mortality in elderly patients with dementia-related psychosis
- Impulse control disorders (pathological gambling, compulsive behaviors) are a recognized adverse effect requiring monitoring
Indications
Aripiprazole is approved for multiple psychiatric indications:
- Schizophrenia: Treatment of acute and maintenance therapy in adults and adolescents (age 13 and older)
- Bipolar I disorder: Acute treatment of manic and mixed episodes (monotherapy or adjunct to lithium or valproate); maintenance monotherapy; acute agitation associated with bipolar mania or schizophrenia (intramuscular formulation)
- Major depressive disorder: Adjunctive treatment to antidepressants in adults with inadequate response to antidepressant monotherapy
- Irritability associated with autistic disorder: In pediatric patients (age 6 to 17 years)
- Tourette syndrome: In pediatric patients (age 6 to 18 years)
Off-label uses include treatment-resistant depression, borderline personality disorder, and impulse-control disorders. Long-acting injectable formulations (aripiprazole monohydrate and aripiprazole lauroxil) are available for maintenance treatment of schizophrenia and bipolar I disorder in adults.
Pharmacokinetics
Aripiprazole exhibits the following pharmacokinetic properties:
Absorption: Well absorbed after oral administration with 87% bioavailability. Peak plasma concentrations occur 3 to 5 hours after dosing. Food does not significantly affect absorption.
Distribution: High volume of distribution (4.9 L/kg) with greater than 99% protein binding, primarily to albumin. Aripiprazole crosses the blood-brain barrier and is distributed into breast milk.
Metabolism: Extensively metabolized in the liver via CYP2D6 and CYP3A4. The major metabolite, dehydro-aripiprazole, has similar pharmacologic activity and represents approximately 40% of the parent drug exposure in plasma. The half-life of aripiprazole is approximately 75 hours, and dehydro-aripiprazole has a half-life of approximately 94 hours.
Excretion: Approximately 25% excreted in urine and 55% in feces. Less than 1% is excreted unchanged in urine.
Special populations: CYP2D6 poor metabolizers have approximately doubled aripiprazole concentrations. Dosage adjustment is required when used with strong CYP2D6 or CYP3A4 inhibitors or inducers. The long half-life allows once-daily dosing and results in steady state being achieved in approximately 2 weeks.
Adverse effects
Aripiprazole has a distinct side effect profile compared to other atypical antipsychotics:
Common adverse effects
- Akathisia (restlessness, inability to sit still): Most common and dose-related; occurs in 10-25% of patients and is the most frequent reason for discontinuation
- Nausea and vomiting: Particularly during initiation
- Headache
- Insomnia or somnolence
- Anxiety and restlessness
- Constipation
Serious adverse effects
- Neuroleptic malignant syndrome (NMS): Rare but life-threatening; presents with hyperthermia, muscle rigidity, altered mental status, autonomic instability, elevated creatine kinase
- Tardive dyskinesia: Risk increases with duration of treatment; lower risk than typical antipsychotics but still present
- Metabolic effects: Lower risk of weight gain, hyperglycemia, and dyslipidemia compared to olanzapine, clozapine, and quetiapine, but monitoring is still recommended
- Orthostatic hypotension: Less common than with other atypicals due to minimal alpha-1 blockade
- Seizures: May lower seizure threshold
- Impulse control disorders: Pathological gambling, compulsive eating, shopping, and hypersexuality reported; monitor patients for new or worsening urges
Notable absences
- Minimal prolactin elevation: Unlike most D2 antagonists, aripiprazole may actually lower prolactin due to its partial agonist activity
- Low weight gain risk: Average weight gain is significantly less than olanzapine, clozapine, or quetiapine
- Minimal sedation: Due to low H1 affinity
- Minimal anticholinergic effects: Due to low muscarinic affinity
Black box warning: Increased mortality in elderly patients with dementia-related psychosis (class warning for all antipsychotics). Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.
Contraindications and warnings
Absolute contraindications:
- Known hypersensitivity to aripiprazole or any formulation component
Warnings and precautions:
- Elderly patients with dementia-related psychosis: Increased risk of death; not approved for this indication
- Cardiovascular disease: Use with caution in patients with known cardiovascular or cerebrovascular disease; may cause orthostatic hypotension
- Seizure disorders: May lower seizure threshold; use cautiously in patients with history of seizures or conditions that lower seizure threshold
- Diabetes and hyperglycemia: Monitor glucose in patients with diabetes or at risk; atypical antipsychotics have been associated with hyperglycemia and diabetes
- Dysphagia: Use cautiously in patients at risk for aspiration pneumonia
- Leukopenia, neutropenia, agranulocytosis: Monitor complete blood count in patients with pre-existing low white blood cell count or history of drug-induced leukopenia
- Hyperprolactinemia-related conditions: Although aripiprazole typically lowers prolactin, consider this in patients with prolactin-dependent tumors
- Body temperature regulation: May disrupt the body's ability to reduce core temperature; caution with strenuous exercise, heat exposure, dehydration, or anticholinergic medications
Pregnancy and lactation: Pregnancy category C. Neonates exposed during the third trimester are at risk for extrapyramidal and withdrawal symptoms. Aripiprazole is excreted in breast milk; weigh benefits versus risks. Consider enrollment in the National Pregnancy Registry for Atypical Antipsychotics.
Drug interactions
Aripiprazole is subject to significant drug interactions due to its metabolism via CYP2D6 and CYP3A4:
CYP3A4 inhibitors
Strong inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): Increase aripiprazole concentrations. Reduce aripiprazole dose by 50% when used concurrently.
CYP2D6 inhibitors
Strong inhibitors (quinidine, fluoxetine, paroxetine): Increase aripiprazole concentrations. Reduce aripiprazole dose by 50% when used concurrently.
Combined CYP3A4 and CYP2D6 inhibition: When strong inhibitors of both enzymes are used together, reduce aripiprazole dose by 75%.
CYP3A4 inducers
Strong inducers (carbamazepine, rifampin, St. John's wort, phenytoin): Decrease aripiprazole concentrations. Double the aripiprazole dose (up to maximum recommended dose) when used concurrently. Reduce dose back to original level when the inducer is discontinued.
Pharmacodynamic interactions
- Antihypertensives: Additive hypotensive effects due to alpha-1 blockade
- CNS depressants (benzodiazepines, alcohol, opioids): Additive sedation and respiratory depression
- Drugs that lower seizure threshold: Additive risk of seizures
- QT-prolonging agents: Although aripiprazole has minimal effect on QT interval, caution is advised with other QT-prolonging drugs
Other interactions
Lorazepam injection: Coadministration with intramuscular aripiprazole resulted in increased sedation and orthostatic hypotension in clinical studies; monitor vital signs if combination is necessary.
Clinical pearls
- Akathisia management: The most common side effect; consider dose reduction, switching to another agent, or adding a beta-blocker (propranolol) or benzodiazepine for symptomatic relief
- Activation versus sedation: Unlike sedating antipsychotics, aripiprazole may cause initial activation, insomnia, or restlessness; consider morning dosing if insomnia occurs
- Metabolic advantages: Preferred in patients at high risk for metabolic syndrome, diabetes, or significant weight gain; better metabolic profile than olanzapine, clozapine, and quetiapine
- Prolactin effects: May be preferred in patients with hyperprolactinemia or prolactin-related side effects (galactorrhea, amenorrhea, sexual dysfunction) from other antipsychotics
- Long half-life: Steady state takes 2 weeks; therapeutic effects may not be fully apparent for several weeks; similarly, side effects may persist for weeks after discontinuation
- Switching strategies: When switching from a full D2 antagonist, patients may experience transient worsening due to relative decrease in dopamine blockade; cross-titration is often preferred
- Impulse control monitoring: Specifically ask about gambling, shopping, eating, and sexual urges; dose reduction or discontinuation may be necessary if these emerge
- Augmentation strategy: When used adjunctively for depression, aripiprazole is typically added to an existing antidepressant rather than used as monotherapy
- Long-acting injectable: Available formulations (once-monthly aripiprazole monohydrate, monthly or every-6-weeks lauroxil) improve adherence in schizophrenia and bipolar disorder; require oral overlap for 2 weeks
- CYP2D6 polymorphism: Poor metabolizers have doubled drug exposure; consider genetic testing or empiric dose reduction if side effects are excessive at standard doses
Practice questions
1. A 32-year-old man with schizophrenia is started on aripiprazole after experiencing significant weight gain and elevated fasting glucose on olanzapine. Four days after starting aripiprazole, he returns to the clinic complaining of an inability to sit still, constant pacing, and inner restlessness. His vital signs are normal, and neurologic examination shows no rigidity or tremor. What is the most appropriate next step in management?
2. A 45-year-old woman with bipolar I disorder maintained on aripiprazole 15 mg daily is prescribed fluoxetine 40 mg daily by her primary care physician for comorbid depression. Two weeks later, she develops worsening akathisia and tremor. Her psychiatrist notes that fluoxetine is a strong CYP2D6 inhibitor. What is the most appropriate adjustment to her aripiprazole regimen?
3. A 28-year-old man with schizophrenia stabilized on aripiprazole 20 mg daily for 6 months presents with new-onset compulsive behaviors. Over the past 2 months, he has spent increasing amounts of time and money gambling online, which is out of character for him and causing financial problems. He denies manic symptoms, and his psychotic symptoms remain controlled. What is the most appropriate management?
Frequently asked questions
How does aripiprazole work?
Aripiprazole works as a partial agonist at dopamine D2 receptors, acting as a functional antagonist in areas of high dopamine activity and providing modest stimulation in areas of low dopamine tone. This dopamine system stabilizer mechanism differs from traditional full antagonists. It also acts as a partial agonist at serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, contributing to its efficacy and side effect profile.
What are the side effects of aripiprazole?
The most common side effect is akathisia (restlessness), occurring in 10-25% of patients. Other frequent effects include nausea, headache, insomnia, and anxiety. Importantly, aripiprazole has a lower risk of weight gain, metabolic syndrome, and prolactin elevation compared to other atypical antipsychotics. Serious but rare risks include neuroleptic malignant syndrome, tardive dyskinesia, and impulse control disorders such as pathological gambling. It carries a black box warning for increased mortality in elderly patients with dementia-related psychosis.
Is aripiprazole a controlled substance?
No, aripiprazole is not a controlled substance. It is an atypical antipsychotic medication that does not have abuse potential or risk of physical dependence. However, it is a prescription medication that requires monitoring by a healthcare provider, and abrupt discontinuation may lead to withdrawal symptoms or relapse of the underlying psychiatric condition.
What is aripiprazole used for?
Aripiprazole is FDA-approved for schizophrenia, acute manic and mixed episodes of bipolar I disorder, maintenance treatment of bipolar I disorder, and adjunctive treatment of major depressive disorder in adults. It is also approved for irritability associated with autistic disorder and Tourette syndrome in pediatric patients. Long-acting injectable formulations are available for maintenance treatment of schizophrenia and bipolar disorder. Off-label uses include treatment-resistant depression and impulse-control disorders.
Aripiprazole vs olanzapine — what is the difference?
The key difference is mechanism and side effect profile. Aripiprazole is a dopamine partial agonist with minimal metabolic effects, low weight gain risk, and no prolactin elevation, but higher rates of akathisia. Olanzapine is a full D2 antagonist with strong 5-HT2A, H1, and muscarinic antagonism, causing significant weight gain, metabolic syndrome risk, sedation, and anticholinergic effects, but generally better tolerability regarding akathisia. Olanzapine may be more sedating and effective for acute agitation, while aripiprazole is preferred when metabolic risk is a concern.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05AX12
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.